Health Care • Biotechnology: Pharmaceutical Preparations
$14.24 ▼ -0.35
(-2.40%)
MKT CAP: $905.6M • VOL: 896.1K
52W L $8 52W H $28
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
JBIO // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$113.5M | -$74.6M | -$81.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$127.4M | -$69.6M | -$75.5M |
| EBITDA (Normalized) | -$113.4M | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$94.7M | -$71.2M | -$56.8M |
| Capital Expenditures (CapEx) | $196.0K | — | — |
| Free Cash Flow (FCF) | -$94.9M | -$71.2M | -$56.8M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -36.7% | -45.0% | — |
| Cash & Short-Term Equivalents | $88.4M | $69.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $332.5M | -$46.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR JBIO.